PEPLOMYCIN SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C61H88N18O21S2.H2O4S
Molecular Weight	1571.668
Optical Activity	UNSPECIFIED
Defined Stereocenters	20 / 20
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2O[C@H]3O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]3O)C4=CN=CN4)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCN[C@@H](C)C7=CC=CC=C7

InChI

InChIKey=ZHHIHQFAUZZMTG-BSVJBJGJSA-N

InChI=1S/C61H88N18O21S2.H2O4S/c1-24-39(76-52(79-50(24)64)31(16-37(63)83)71-17-30(62)51(65)89)56(93)78-41(47(32-18-67-23-72-32)98-60-49(45(87)43(85)35(19-80)97-60)99-59-46(88)48(100-61(66)95)44(86)36(20-81)96-59)57(94)73-27(4)42(84)25(2)53(90)77-40(28(5)82)55(92)70-15-12-38-74-34(22-101-38)58-75-33(21-102-58)54(91)69-14-9-13-68-26(3)29-10-7-6-8-11-29;1-5(2,3)4/h6-8,10-11,18,21-23,25-28,30-31,35-36,40-49,59-60,68,71,80-82,84-88H,9,12-17,19-20,62H2,1-5H3,(H2,63,83)(H2,65,89)(H2,66,95)(H,67,72)(H,69,91)(H,70,92)(H,73,94)(H,77,90)(H,78,93)(H2,64,76,79);(H2,1,2,3,4)/t25-,26-,27+,28+,30-,31-,35-,36+,40-,41-,42-,43+,44+,45-,46-,47-,48-,49-,59+,60-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C61H88N18O21S2
Molecular Weight	1473.589
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	20 / 20
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.anticancer-drug.net/antibiotic/peplomycin.htm
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/83987 | http://www.rad-ar.or.jp/siori/kekka.cgi?n=39236

Peplomycin has been developed as novel analog of bleomycin, which has less pulmonary toxicity than bleomycin. Peplomycin has been the subject of extensive studies in Japan and Europe. It is indicated for the treatment of malignant lymphoma, head and neck cancer, lung cancer, prostate cancer and skin cancer. General side effects are: digestive symptoms such as stomatitis, anorexia, nausea/vomiting, general malaise, depilation, fever, chills etc.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Synthesis of DNA 4 Target ID: WP1925 Sources: http://www.anticancer-drug.net/antibiotic/peplomycin.htm \| https://www.ncbi.nlm.nih.gov/pubmed/83987	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Prostate cancer 186 Sources: http://www.rad-ar.or.jp/siori/kekka.cgi?n=39236	Primary	Approved 8583	Pepleo Approved Use It is used for the treatment of skin cancer, head and neck malignancy, lung cancer, prostate cancer, malignant lymphoma
Lung cancer 70 Sources: http://www.rad-ar.or.jp/siori/kekka.cgi?n=39236	Primary	Approved 8583	Pepleo Approved Use It is used for the treatment of skin cancer, head and neck malignancy, lung cancer, prostate cancer, malignant lymphoma
Malignant lymphoma 10 Sources: http://www.rad-ar.or.jp/siori/kekka.cgi?n=39236	Primary	Approved 8583	Pepleo Approved Use It is used for the treatment of skin cancer, head and neck malignancy, lung cancer, prostate cancer, malignant lymphoma
Skin cancer 23 Sources: http://www.rad-ar.or.jp/siori/kekka.cgi?n=39236	Primary	Approved 8583	Pepleo Approved Use It is used for the treatment of skin cancer, head and neck malignancy, lung cancer, prostate cancer, malignant lymphoma
Head and neck cancer 50 Sources: http://www.rad-ar.or.jp/siori/kekka.cgi?n=39236	Primary	Approved 8583	Pepleo Approved Use It is used for the treatment of skin cancer, head and neck malignancy, lung cancer, prostate cancer, malignant lymphoma

PubMed

Title	Date	PubMed
A review of clinical studies of pepleomycin.	1980	6160600
Effect of pepleomycin in prostatic cancer. A preliminary report.	1980	6163206
Biological studies on the degradation products of 3-[(S)-1'-phenylethylamino]propylaminobleomycin: a novel analog (pepleomycin).	1979-01	83987

Patents

Sample Use Guides

In Vivo Use Guide

3.2 mg/m2 once a day, 2-3 times per week (22.4 mg/m2 per week)

Route of Administration: Other

In Vitro Use Guide

Peplomycin showed the following antimicrobial potency against Mycobacterium smegmatis ATCC 607 – 873 ug potency/mg and gave the following very correlative result on the growth inhibition of cultured HeLa S3 cells – ID50 = 0.84 ug/ml.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:55:32 GMT 2025` Edited by `admin` on `Mon Mar 31 17:55:32 GMT 2025`
Record UNII	6A668951HW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PEPLEO

Preferred Name

English

PEPLOMYCIN SULFATE

Official Name

English

N1-[3-[[(S)-(?-Methylbenzyl)]amino]propyl]bleomycinamide sulfate (1:1) (salt)

Common Name

English

PEPLOMYCIN SULFATE SALT [MI]

Common Name

English

Peplomycin sulfate [WHO-DD]

Common Name

English

NSC-276382

Code

English

PEPLOMYCIN SULFATE [USAN]

Common Name

English

PEPLOMYCIN SULFATE [JAN]

Common Name

English

NK-631

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C2311